The process of developing cell lines and screened clones that express with high productivity and stability can be both time-consuming and labor-intensive. Our CHOSOURCE™ platform is a state-of-the-art expression system that redefines the landscape of biotherapeutics development, and manufacturing.
With over 100 licensees worldwide and more than 60 regulatory filings across multiple territories since 2018, the CHOSOURCE expression platform boasts a proven track record with full traceability, and reliable results.
Our flexible licensing terms provide easy accessibility to this high-performance platform, aware of the demands of cost-effective biomanufacturing. The CHOSOURCE platform is also compatible with existing customer workflows, offering convenience and flexibility.
Our expression systems are your go-to solution for streamlining from development through manufacturing of biotherapeutics, offering speed, reliability, and adaptability of your workflow.
The CHOSOURCE™ Platform is available for research, clinical, diagnostic, and commercialization applications, including services, under specific licenses from Revvity.
